ArticleScientific reports2025
Association of neutrophil percentage-to-albumin ratio with distant metastasis and survival outcomes in breast cancer patients: a retrospective and prospective cohort study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Preoperative lymphocyte-albumin-monocyte index as an inflammation- and nutrition-based predictor of overall survival in triple-negative breast cancer: A retrospective cohort study.Oncology letters · 2026Article
- Neutrophil Percentage-to-Albumin Ratio as a Prognostic and Predictive Biomarker in Non-Metastatic Breast Cancer Treated with Neoadjuvant Chemotherapy: Findings from a Retrospective Cohort.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is the most common malignancy in women worldwide, with distant metastasis being the leading cause of BC-related mortality. The neutrophil percentage-to-albumin ratio (NPAR), reflecting systemic inflammation and nutritional status, has shown prognostic potential in other cancers, but its role in BC remains unclear. We conducted a single-center retrospective and prospective cohort study including 348 invasive BC patients admitted between 2016 and 2023. Baseline NPAR was calculated before treatment. Logistic regression and restricted cubic spline analyses were used to assess associations between NPAR and distant metastasis risk. For metastatic patients, overall survival (OS) was evaluated prospectively through outpatient visits, telephone contact, and review of medical records using Kaplan-Meier curves and Cox regression. NPAR was significantly higher in metastatic than non-metastatic patients [median 15.9 vs. 15.0, P < 0.001]. Each SD increase in NPAR was associated with 65% higher odds of distant metastasis (adjusted OR 1.647, 95% CI 1.275-2.162). Using the cutoff of 17.7, high NPAR predicted a fourfold higher metastasis risk (OR 4.136, 95% CI 2.231-7.961). Among metastatic patients, high NPAR was linked to shorter OS (45 vs. 63 months; log-rank P = 0.036) and doubled mortality risk (HR 2.064, 95% CI 1.022-4.169). Baseline NPAR is an independent predictor of metastasis risk and survival in BC. As a simple, inexpensive, and clinically available biomarker, NPAR may facilitate early risk stratification and guide personalized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.